ß-Thujaplicin exerts its anticancer activity through a wider variety of mechanisms, including induction of cell cycle arrest & programmed cell death [14–16], inhibiting cancer cell migration and metastasis [17, 18], impairing DNA damage response by inhibiting homologous recombination [19], epigenetic modification by inhibition of DNA methyltransferase 1 [20] and targeting of cancer stem cells by RNA interference [21] and inhibition of vasculogenic mimicry [22]. The gene discussed is DNMT1; the disease is cancer.